Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Tocilizumab in COVID-19 Pneumonia
NCT04346355Phase 2Terminated
- Sponsor
- Azienda USL-IRCCS di Reggio Emilia
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in COVID-19 pneumonia, sponsored by Azienda USL-IRCCS di Reggio Emilia. Started Mar 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04346355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346355.